We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Elusive Therapeutic Effect of PCSK9 Inhibitors on Lipoprotein(a) Levels.
- Authors
Sbrana, Francesco; Bigazzi, Federico; Dal Pino, Beatrice; Toma, Maddalena; Ripoli, Andrea; Sampietro, Tiziana
- Abstract
Highlights from the article: Lipoprotein (a) [Lp(a)] is a prevalent genetic risk factor for coronary artery disease [1] and proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) have demonstrated significant Lp(a)-lowering effects [[2]]. All patients were assigned to PCSK9i treatment every 2 weeks (evolocumab 140 mg in 14, alirocumab 150 mg in 5, or alirocumab 75 mg in 2 subjects), on top of lipid-lowering-therapy (statins in 15, ezetimibe in 9, fibrates in 3 subjects; 3 subjects were not on lipid-lowering drugs due to pharmacologic intolerance). In these subjects PCSK9i was administered at the end of the apheresis session and LA was performed, with 14-day inter-apheresis interval, by dextran-sulphate absorption from plasma (8 patients), or heparin-induced LDL precipitation apheresis (2 patients).
- Subjects
LIPOPROTEIN A; LIPOPROTEINS; CARDIAC patients
- Publication
Therapeutic Apheresis & Dialysis, 2019, Vol 23, Issue 4, p385
- ISSN
1744-9979
- Publication type
Article
- DOI
10.1111/1744-9987.12766